The United Kingdom and the United States have hammered out a significant trade agreement that will maintain no import taxes on UK medicine products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the NHS. This commitment ensures that duties on these vital products will be held at nothing for a period of the next three years.
This agreement comes after recent statements to significantly raise duties on branded drug products, with figures floated up to double the cost.
"This deal between the United Kingdom strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue balance to transatlantic medicine commerce," a release noted.
Commercial Significance
Drugs constitute one of the Britain's most significant goods shipped to the America, which is easily the biggest buyer for leading companies like GSK and AstraZeneca.
Export figures show that in the one-year period to the end of last September, the UK shipped drugs totaling billions to the US. This amount accounted for a significant portion of British export trade in that span.
"This guarantee safeguards employment, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for life sciences," a government official remarked.
Key UK Commitments
The agreement includes several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to double overall health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, refunds exceeded 20%.
Industry Background
The pact comes amid a protracted dispute between the drug companies and the ministers over drug pricing and approval rates.
These tensions were exacerbated by arguments that American consumers were charged several times more for the identical medicines than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or scrapped, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
